Loading...

ORMP ORAMED PHARMACEUTICALS INC Operational Disruptions 8-K Filing

RMD

RMP

ORAMED PHARMACEUTICALS INC

(ORMP)

2023 8-K

Financial Results Report

Dividend Announcement

Share Repurchase Agreement

Warrants Repurchase

Stockholder Meeting Summary

Asset Acquisitions

Royalty Agreement

License Agreement

Joint Venture Agreement

Payment Deferral Agreement

Securities Agreement

Securities Agreement

Clinical Trial Agreement

Securities Agreement

Annual Meeting of Stockholders

Stock Buyback Program

Merger of Equals

Appointment of CFO

Resignation of CFO

Payment Received

Investment Deal

Appointment of Director

Agreement for Stock Offering

Joint Venture Agreement

Resignation of Director

Investment Deal

Appointment of Director

Acquisition Agreement Termi...

Stock Purchase Agreement

Amendment to Stock Purchase...

Stock Purchase Agreement

Share Purchase Term Sheet

Appointment of Director

Amendments to Bylaws

Phase 3 Clinical Trial Results

External Links:

ORAMED PHARMACEUTICALS INC. announced Phase 3 results of its clinical trial for its oral insulin capsule, ORMP-0801, which did not meet its primary and secondary endpoints, leading to the discontinuation of its oral insulin clinical activities for Type 2 Diabetes.

AI Assistant

ORAMED PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.